Is the worst finally over for CSL shares?

Has the share price finally bottomed?

Key points
  • Shares dipped 0.11%, following a recent 3.64% monthly rise, suggesting possible stabilisation after prior sell-offs due to disappointing FY25 results and guidance downgrades.
  • After a recent 7% recovery, analysts are optimistic about CSL's prospects, noting increased investor interest with an average target price implying a 51.57% upside.
  • Macquarie and UBS rate CSL as a buy with targets around $275, suggesting a 50% gain potential, supported by positive sentiment from Red Leaf Securities.

CSL Ltd (ASX: CSL) shares dipped 0.11% for the day on Tuesday. At the close of the ASX, the share price was $183.44. The decline is small though, and off the back of a 3.64% increase over the past month it sparks the question: Have CSL shares finally reached the bottom?

A young man wearing a backpack in a city street crosses his fingers and hopes for the best.

Image source: Getty Images

What happened to CSL shares?

The biotech company's shares suffered a brutal sell-off in mid-August. This followed CSL's FY25 results, where a surprise restructure announcement strategic demerger sparked an investor panic. Investors weren't happy with the announcement and sold off their shares in fear. As a result, the CSL share price lost around a fifth of its value within just one week. At the time, analysts said the investor reaction was overdone and unwarranted. 

Just two and a half months later, in late-October, the company's share price dropped another 19.2% to a seven-year low after it downgraded its FY26 revenue and profit growth guidance. Management had originally forecast an FY26 revenue growth of 4-5% and forecast net profit after tax before amortisation (NPATA) to grow 7-10%. But in October this was downgraded to FY26 revenue guidance of 2-3% and NPATA growth guidance of 4-7%. CSL also said its planned demerger of its Seqirus business will be pushed back.

Have CSL shares finally reached the bottom?

Despite a cluster of headwinds facing the business this year, and a downwards spiral of the CSL share price, it looks like we could be beginning to see green shoots of recovery.

Since the latest price plunge, CSL shares have climbed just over 7%. While the share price has fallen a little further today, I'm optimistic investor sentiment is turning a corner. CSL shares were the fifth most-traded by CommSec clients last week, over half of which was buying activity. If investor interest begins to pick up, it could mean that the share price does too. 

Analysts appear to be bullish about the stock too. Tradingview data shows that out of 18 analysts, 1 have a buy or strong buy rating on CSL shares. The remaining 4 have a hold rating.

The average target price for the stock is $242.20, but some expect this could be as high as $278.05 over the next 12 months. At the time of writing this implies a huge potential 51.57% upside for investors. 

Macquarie and UBS have a buy rating on CSL shares and a 12-month price target of $275.20 and $275 respectively. This suggests a potential 50% gain from here.

The team at Red Leaf Securities thinks that the biotech giant has been oversold and have named it as an ASX share to buy this week.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

rubbish bins
Opinions

I've always loved Wesfarmers shares. But after a trip to Kmart, I'm not so sure

A weekend trip took some gloss off this stock.

Read more »

Piles of increasing coins alongside an hourglass.
Opinions

Why I'm planning to buy more Soul Patts shares in 2027

I think Soul Patts is a great long-term buy.

Read more »

a close up of a woman's face looks skywards as she is showered in a sea of graphic symbols of gold and silver coins bearing the bitcoin logo.
Cryptocurrencies

Are you a 'greater fool' for owning Bitcoin?

Is Bitcoin truly an investment?

Read more »

A woman in a red dress holding up a red graph.
Opinions

I went looking for shares which could double by 2030. These 3 made my shortlist

All of these shares are in recovery mode.

Read more »

A little girl is surprised at a science experiment.
Opinions

2 ASX shares with the potential to double in a year, and the risk that keeps me cautious

One of these ASX shares could climb up to 123% higher.

Read more »

A man in business attire plunges into water.
Opinions

My 2027 ASX shortlist started with 50 shares. It ended with these 3

There's no such thing as a perfect ASX share, but these three tick my boxes.

Read more »

A man in a business suit uses a rope to climb up the side of a huge pile of papers fashioned like a tall building against a blue sky backdrop with clouds representing an assessment of whether CBA shares stacked up well in March
Opinions

CBA shares: I investigated the bull and bear case. Here's my verdict

The market is split, so I did my own research.

Read more »

A couple hang off their car looking at the sun rising over the horizon.
Opinions

There's one ASX share I'd happily hold for 10 years. This is it

I think this ASX share can stand the test of time.

Read more »